Few places are considered off limits for Australian mining companies operating in Africa, including Eritrea, one of the most repressed and politically unstable places in the world.
It’s the new frontier for Australian mining but our fraught expansion into Africa now goes back decades, and early missteps in the continent are proving hard to shake off.
Mining in Africa's developing nations can be fraught, with both small cap companies and governments looking to make sizable profits. But who are the winners and losers in this mad dash for cash?
If Novo Nordisk is to fulfil the potential of its anti-obesity drug Saxenda, it needs more doctors to have a new understanding of how obesity really works. And to prescribe. Again and again.
The race to find a pharmacological way to combat obesity is on — and in addition to financial pressures, it has proven devilishly difficult to make an obesity drug that is effective, safe and works at scale, across a population.
Getting doctors and medical bodies to classify obesity as a 'disease' would be a huge win for pharmaceutical companies. Here's how they're trying to do just that.
One hundred and fifty-four brothers have been accused of sexually assaulting students at Marist schools, but their identity and whether they are still teaching remains a secret.
Shareholders are demanding real action on climate change, but how can they make businesses deliver?
The government's latest welfare experiment looks to the gig economy for answers, but there are concerns that it will push jobseekers into dangerous, underpaid and exploitative work.